London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

近日，葛兰素史克（GSK）与映恩生物就一项ADC药物 (DB-1324)，达成独家授权协议。根据协议，GSK将获得该药全球（不包括中国大陆、香港地区和澳门地区）的独家授权，以推进该ADC药物的研发与商业化进程。

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

今日（12月6日），中国国家药监局药品审评中心（CDE）官网最新公示显示，葛兰素史克（GSK）申报的注射用玛贝兰妥单抗上市申请获得受理。公开资料显示，这是GSK在研的Blenrep（belantamab ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...

GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...

Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first ...

GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.

葛兰素史克称，Blenrep在与另一种名为BorDex的癌症疗法联合使用时，帮助那些骨髓瘤复发的患者们延长了寿命。这家英国制药巨头表示，后期临床试验 ...